Description
Testosterone Enanthate 300 is a specific formulation of testosterone, typically administered through intramuscular injection, that contains 300 milligrams of testosterone per milliliter (mL). It shares the same benefits as other forms of testosterone when used for legitimate medical purposes, such as hormone replacement therapy (HRT) to treat individuals with low testosterone levels, a condition known as hypogonadism. Here are some potential benefits of Testosterone Enanthate 300 when used for medical reasons:
Correction of Low Testosterone Levels: Testosterone Enanthate 300 is primarily used to treat individuals with low testosterone levels, which can result from conditions like hypogonadism. Restoring testosterone levels to the normal range can help alleviate symptoms associated with low testosterone, including fatigue, low libido, and mood changes.
Increased Muscle Mass and Strength: Like other forms of testosterone, Testosterone Enanthate 300 can promote muscle growth and an increase in strength. This is particularly beneficial for individuals with muscle-wasting conditions.
Improved Bone Density: Testosterone plays a role in maintaining bone density, and its use may help prevent bone loss in conditions such as osteoporosis.
Increased Red Blood Cell Production: Testosterone can stimulate the production of red blood cells, which can be beneficial for individuals with anemia.
Hormone Regulation: Testosterone regulates various physiological processes, including the distribution of fat, red blood cell production, and the development of secondary sexual characteristics in males.
Improved Well-Being: Some individuals on hormone replacement therapy with Testosterone Enanthate 300 report an improved sense of well-being, increased energy, and enhanced mood.
History
Testosterone enanthate is a heptanoate ester and a sterol ester. It has a role as an androgen. It derives from a testosterone.|Testosterone enanthate is an esterified variant of testosterone that comes as an injectable compound with a slow release rate. It is the first injectable ester preparation of testosterone. This slow release is achieved by the presence of the enanthate ester functional group attached to the testosterone molecule.
This testosterone derivative was first approved on December 24, 1953. In 2017, about 6.5 million retail prescriptions for testosterone therapy were filled. The majority of the prescriptions written were for injectable (66%) and topical (32%) testosterone products. As recent as 1 October 2018, the US FDA approved Antares Pharma Inc.'s Xyosted - a subcutaneous testosterone enanthate product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable autoinjector. As the first subcutaneous autoinjector product designed for testosterone replacement therapy, this innovative formulation removes transfer concerns commonly associated with testosterone gels and potentially reduces the need for in-office/in-clinic injection procedures that may inconvenience patients with frequent visits to the clinic.
Testosterone Enanthate is a long-acting intramuscular form of the androgen testosterone. Testosterone inhibits gonadotropin secretion from the pituitary gland and ablates estrogen production in the ovaries, thereby decreasing endogenous estrogen levels. In addition, this agent promotes the maintenance of male sex characteristics and is indicated for testosterone replacement in hypogonadal males, delayed puberty, and metastatic mammary cancer.
Drug Indication
Testosterone enanthate in males is indicated as a replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. Some of the treated conditions are 1) primary hypogonadism, defined as testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome or orchidectomy; 2) hypogonadotropic hypogonadism due to an idiopathic gonadotropin or luteinizing hormone-releasing hormone deficiency or due to a pituitary-hypothalamic injury from tumors, trauma or radiation, in this case it is important to accompany the treatment with adrenal cortical and thyroid hormone replacement therapy; 3) to stimulate puberty in patients with delayed puberty not secondary to a pathological disorder. If the conditions 1 and 2 occur prior to puberty, the androgen replacement therapy will be needed during adolescent years for the development of secondary sexual characteristics and prolonged androgen treatment might be needed it to maintain sexual characteristics after puberty.
In females, testosterone enanthate is indicated to be used secondarily in presence of advanced inoperable metastatic mammary cancer in women who are from one to five years postmenopausal. It has also been used in premenopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormone-responsive tumor. Testosterone enanthate injections that are currently formulated for subcutaneous use are specifically indicated only for primary hypogonadism and hypogonadotropic hypogonadism. The use of such formulations is limited because the safety and efficacy of these subcutaneous products in adult males with late-onset hypogonadism and males less than 18 years old have not yet been established.
Pharmacology:
Testosterone enanthate presents the same properties as its analog testosterone with the advantage that this molecule has a longer release rate and half-life. Administration of ester derivatives of testosterone as testosterone enanthate generates an increase in serum testosterone to levels reaching 400% from the baseline within 24 hours of administration. These androgen levels remain elevated for 3-5 days after initial administration. Continuous administration of testosterone enanthate shows a significant suppression of dihydrotestosterone, serum PSA, HDL and FSH, as well as a slight increase in serum estradiol. The levels of dihydrotestosterone and FSH can remain suppressed even 14 days after treatment termination. There are no changes in mood and sexual activity by the presence of testosterone enanthate.
Hot Products
| ID | Item | Capacity |
| 1 | Anavar | 25mg*100 |
| 2 | Anavar | 50mg*100 |
| 3 | Winstrol | 10mg*100 |
| 4 | Winstrol | 20mg*100 |
| 5 | Winstrol | 50mg*100 |
| 6 | Proviron | 50mg*100 |
| 7 | Dianabol | 25mg*100 |
| 8 | Turinabol | 40mg*100 |
| 9 | Aromasin | 25mg*100 |
| 10 | Anadrol | 50mg*100 |
| 11 | Clomid | 50mg*100 |
| 12 | Nolvadex | 20mg*100 |
| 13 | Arimidex | 1mg*100 |
| 14 | Clenbuterol | 40ug*100 |
| 15 | 2,4-DNP | 200mg*50 |
| 16 | Halotestin | 10mg*100 |
| 17 | Cialis | 20mg*100 |
| 18 | T3 | 50mcg*100 |
| 19 | Cock bombs 20mg+50mg | (20mg cialis+50mg viagra)*100 |
| 20 | Methyltest | 10mg*100 |
| 21 | Viagra | 100mg*100 |
| 22 | Letrozole | 2.5mg*100 |
| 23 | Methyltrienolone | 500ug*100 |
| 24 | Superdrol(methasterone) | 10mg*100 |
| 25 | Dostinex(cabergoline) | 0.5mg*25 |
| ID | Item | Capacity |
| 1 | Testosterone enanthate | 250mg/ml |
| 2 | Testosterone propionate | 100mg/ml |
| 3 | Testosterone cypionate | 200mg/ml |
| 4 | Testosterone undecatate | 250mg/ml |
| 5 | Nandrolone Decanoate | 400mg/ml |
| 6 | Boldenolone Undecylenate | 400mg/ml |
| 7 | Boldenolone Cypionate | 300mg/ml |
| 8 | Stanozolol | 50mg/ml |
| 9 | Sustan 350 | 350mg/ml |
| 10 | Drostanolone enanthate | 200mg/ml |
| 11 | Drostanolone prop(masteron) | 100mg/ml |
| 12 | Trenbolone Ace | 100mg/ml |
| 13 | Trenbolone Enan | 200mg/ml |
| 14 | Methenolone enanthate | 100mg/ml |
| 15 | NPP | 100mg/ml |
| 16 | Trenbolone Hex(parabolan) | 100mg/ml |
| 17 | Trenbolone Mix(blend of 3) | 200mg/ml |
| 18 | Testosterone Base | 100mg/ml |
Any needs, please contact me
Email: amyraws195@gmail.com
Whatsapp: +86-17507125642
Telegram: +86-17507125642
Hot Tags: te300 finished oil, China te300 finished oil manufacturers, suppliers, factory, 2022 Testosterone Cypionate, SUS300 STERILE US Domestic, 2022 Trestolone Acetate MENT50, Testosterone Propionate CAS 57 85 2 200mg, Testosterone Enantate Hepius 250mg ml 10ml, Trestolone Acetate MENT50 CAS 10161 34 9












